Q2 EPS Forecast for Halozyme Therapeutics Lowered by Analyst

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities research analysts at Zacks Research lowered their Q2 2025 earnings estimates for shares of Halozyme Therapeutics in a research report issued to clients and investors on Wednesday, February 5th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn $1.06 per share for the quarter, down from their previous forecast of $1.07. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.87 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q3 2025 earnings at $1.14 EPS and Q4 2026 earnings at $1.78 EPS.

Several other research analysts also recently weighed in on HALO. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Wells Fargo & Company reduced their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. JMP Securities upped their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday. Finally, Piper Sandler upped their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $60.89.

Halozyme Therapeutics Stock Down 1.4 %

HALO opened at $57.10 on Friday. Halozyme Therapeutics has a twelve month low of $34.36 and a twelve month high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The company has a 50-day moving average price of $51.37 and a 200 day moving average price of $54.40. The company has a market cap of $7.26 billion, a PE ratio of 18.91, a price-to-earnings-growth ratio of 0.43 and a beta of 1.25.

Institutional Trading of Halozyme Therapeutics

Hedge funds have recently made changes to their positions in the company. RPg Family Wealth Advisory LLC purchased a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at approximately $1,886,000. Segall Bryant & Hamill LLC grew its stake in shares of Halozyme Therapeutics by 16.3% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock valued at $20,330,000 after buying an additional 49,856 shares during the period. Retirement Systems of Alabama grew its stake in shares of Halozyme Therapeutics by 23.5% in the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock valued at $22,282,000 after buying an additional 74,173 shares during the period. South Street Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $9,812,000. Finally, Foster & Motley Inc. boosted its position in shares of Halozyme Therapeutics by 118.6% during the 4th quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company’s stock worth $1,113,000 after purchasing an additional 12,630 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Activity at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the sale, the director now owns 38,611 shares of the company’s stock, valued at $2,173,799.30. This represents a 11.46 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 2.70% of the stock is owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.